Evidence map›Paper›PMID 25460347›Full record

SynthesisPloS one2014

An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma.

Songlin Peng, Yang Zhao, Feng Xu, Changjun Jia, Yongqing Xu, Chaoliu Dai

Open access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Hepatocellular Carcinoma with Atrial Extension: A Case Report.GE Portuguese journal of gastroenterology · 2021
    Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Systemic therapy for advanced hepatocellular carcinoma: an update.Journal of gastrointestinal oncology · 2017
    Review
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Clinical trials of antiangiogenic therapy for hepatocellular carcinoma.International journal of clinical oncology · 2016
    Review
  18. Review
  19. Article
  20. Surgical Treatment of Hepatocellular Carcinoma.Cancer control : journal of the Moffitt Cancer Center
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Songlin PengDepartment of Hepatobiliary Surgery, The Affiliated Shengjing Hospital of China Medical University, Shenyang 110004, China.
Yang ZhaoDepartment of Hepatobiliary Surgery, The Affiliated Shengjing Hospital of China Medical University, Shenyang 110004, China.
Feng XuDepartment of Hepatobiliary Surgery, The Affiliated Shengjing Hospital of China Medical University, Shenyang 110004, China.
Changjun JiaDepartment of Hepatobiliary Surgery, The Affiliated Shengjing Hospital of China Medical University, Shenyang 110004, China.
Yongqing XuDepartment of Hepatobiliary Surgery, The Affiliated Shengjing Hospital of China Medical University, Shenyang 110004, China.
Chaoliu DaiDepartment of Hepatobiliary Surgery, The Affiliated Shengjing Hospital of China Medical University, Shenyang 110004, China.
China Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC) remains controversial. Therefore, we conducted a meta-analysis to evaluate the efficacy and safety of sorafenib for treating patients with advanced HCC.

methodsThe PubMed, Embase, and Web of Science databases were searched. Eligible studies were randomized controlled trials (RCTs) that assessed sorafenib therapy in patients with advanced HCC. The outcomes included overall survival (OS), time to progression (TTP), overall response rate (ORR), and toxicities. Hazard ratio (HR) and risk ratio (RR) were used for the meta-analysis and were expressed with 95% confidence intervals (CIs).

resultsSeven RCTs, with a total of 3807 patients, were included in this meta-analysis. All patients received sorafenib alone, or with other chemotherapeutic regimens. Pooled estimates showed that sorafenib improved the OS (HR = 0.74, 95% CI: 0.61, 0.90; P = 0.002), or TTP outcomes (HR = 0.69, 95% CI: 0.55, 0.86; P = 0.001). Subgroup analysis revealed that sorafenib was more effective in the patients with an Eastern Cooperative Oncology Group performance status (ECOG PS) of 1-2 (HR = 0.77, 95% CI: 0.60, 1.0; P = 0.05), or macroscopic vascular invasion (MVI), and/or extrahepatic spread (EHS) (H  = 0.65, 95% CI: 0.46, 0.93; P = 0.02), in terms of OS. Patients who received sorafenib did not have a higher ORR (RR = 0.85, 95% CI: 0.65, 1.11; P = 0.10). In addition, there was a slight increase in toxicity in the sorafenib group.

conclusionTreatment with sorafenib significantly improved OS and TTP in patients with advanced HCC. Additional large-scale, well-designed RCTs are needed to evaluate the efficacy of sorafenib-based therapy in the treatment of advanced HCC.

Indexed as

Antineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, HepatocellularDisease ProgressionHumansLiver NeoplasmsNiacinamidePatient SafetyPhenylurea CompoundsPrognosisRandomized Controlled Trials as TopicSorafenibTreatment OutcomeAntineoplastic AgentsNiacinamidePhenylurea CompoundsSorafenib

Identifiers

PMID25460347
PMCPMC4251972
OpenAlexW1996834135

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.